We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+37.44%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.2B
AUM Growth
+$120M
Cap. Flow
-$366M
Cap. Flow %
-16.59%
Top 10 Hldgs %
84.63%
Holding
41
New
11
Increased
2
Reduced
3
Closed
11

Top Buys

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$65M
2
CGON icon
CG Oncology
CGON
+$31.9M
3
ZBIO
Zenas BioPharma
ZBIO
+$26M
4
PCVX icon
Vaxcyte
PCVX
+$20.1M
5
MREO
Mereo BioPharma
MREO
+$15M

Top Sells

Rank Stock Value
1
QURE icon
uniQure
QURE
+$233M
2
TNGX icon
Tango Therapeutics
TNGX
+$89.3M
3
APLS
Apellis Pharmaceuticals
APLS
+$78M
4
XNCR icon
Xencor
XNCR
+$43.2M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$34.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IBIO icon
26
iBio
IBIO
$72M
$4.3M 0.2%
+2,228,000
New +$3.04M
MREO
27
Mereo BioPharma
MREO
$48.2M
$3.27M 0.15%
+7,856,466
New +$15M
CAMP icon
28
CAMP4 Therapeutics
CAMP
$178M
$1.99M 0.09%
+325,000
New +$1.38M
XNCR icon
29
CALL
Xencor
XNCR
$1.47B
$1.03M 0.05%
+67,500
New +$1.01M
SRZNW icon
30
Surrozen Inc Warrant
SRZNW
$75.6K
$100K ﹤0.01%
4,444
-62,221
-93% -$921
ALKS icon
31
Alkermes
ALKS
$8.79B
– –
-500,000
Closed -$15M
APLS
32
DELISTED
Apellis Pharmaceuticals
APLS
– –
-3,447,156
Closed -$78M
CMPS
33
Compass Pathways
CMPS
$1.52B
– –
-265,137
Closed -$1.52M
KURA icon
34
Kura Oncology
KURA
$901M
– –
-872,500
Closed -$7.72M
MDGL icon
35
Madrigal Pharmaceuticals
MDGL
$12.7B
– –
-75,000
Closed -$34.4M
PEPG icon
36
PepGen
PEPG
$131M
– –
-800,000
Closed -$3.7M
PRME icon
37
Prime Medicine
PRME
$544M
– –
-1,543,326
Closed -$8.55M
QURE icon
38
uniQure
QURE
$2.63B
– –
-3,988,971
Closed -$233M
RNAM
39
DELISTED
Avidity Biosciences
RNAM
– –
-765,000
Closed -$33.3M
TNGX icon
40
Tango Therapeutics
TNGX
$4.35B
– –
-10,630,736
Closed -$89.3M
MTSR
41
DELISTED
Metsera Inc
MTSR
– –
-271,529
Closed -$14.2M
1
2

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q4 2025 Portfolio in Review

As of Q4 2025, EcoR1 Capital held 41 positions worth $2.2B, up 5.8% from $2.08B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

EcoR1 Capital withdrew a net $366M in Q4 2025, closing 11 positions and reducing 3 holdings. Its most notable exit was uniQure, an estimated $233M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, EcoR1 Capital opened a new position in CG Oncology worth $32.1M.

  • EcoR1 Capital's largest Q4 2025 buy was CG Oncology: 772,000 shares worth $32.1M.
  • EcoR1 Capital added most to Centessa Pharmaceuticals in Q4 2025, an estimated $65M increase.
  • EcoR1 Capital's biggest Q4 2025 reduction was Xencor, cutting an estimated $43.2M.
  • EcoR1 Capital fully exited uniQure in Q4 2025, selling an estimated $233M.
  • EcoR1 Capital's ten largest holdings make up 85% of its $2.2B portfolio in Q4 2025.
  • EcoR1 Capital opened 11 new positions and closed 11 in Q4 2025.
  • EcoR1 Capital's portfolio value rose 5.8% quarter-over-quarter to $2.2B.

Based on EcoR1 Capital's 13F filing for Q4 2025, filed 17 Feb 2026.